Showing results (161-170 of 207) with videos related to
Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study groupVerena I Gaidzik, Lars Bullinger, Richard F Schlenk, et al.Circulation|December 7, 2005
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicityLeszek Wojnowski, Bettina Kulle, Markus Schirmer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphomaFranck Morschhauser, Françoise Kraeber-Bodéré, William A Wegener, et al.The Lancet. Oncology|September 24, 2011
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) GroupMichael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper, et al.The Lancet. Haematology|February 3, 2022
KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trialsDominic Kaddu-Mulindwa, Bettina Altmann, Sandra Robrecht, et al.Blood Advances|January 4, 2018
Direct evidence for a polygenic etiology in familial multiple myelomaBritt-Marie Halvarsson, Anna-Karin Wihlborg, Mina Ali, et al.Haematologica|November 3, 2009
Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trialsHeinz-Wolfram Bernd, Marita Ziepert, Christoph Thorns, et al.Blood|February 25, 2018
High-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements with diffuse large B-cell lymphoma morphologyDavid W Scott, Rebecca L King, Annette M Staiger, et al.EMBO Molecular Medicine|June 19, 2016
USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphomaKatharina Engel, Martina Rudelius, Jolanta Slawska, et al.The Lancet. Oncology|May 2, 2006
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) GroupMichael Pfreundschuh, Lorenz Trümper, Anders Osterborg, et al.Pageof 21